BACKGROUND AND PURPOSE: Decreased glucose metabolism in the temporal and parietal lobes on FDG-PET is recognized as an early imaging marker for the AD pathology. Our objective was to investigate the effects of age on FDG-PET findings in aMCI. MATERIALS AND METHODS: Twenty-five patients with aMCI at 55-86 years of age (median = 73 years) and 25 age- and sex-matched CN subjects underwent FDG-PET. SPM5 was used to compare the FDG uptake in patients in aMCI-old (>73 years) and aMCI-young (<or=73 years) groups with CN subjects. The findings in the aMCI-old patients were independently validated in a separate cohort of 10 aMCI and 13 CN subjects older than 73 years of age. RESULTS: The pattern of decreased glucose metabolism and gray matter atrophy in the medial temporal, posterior cingulate, precuneus, lateral parietal, and temporal lobes in aMCI-young subjects was consistent with the typical pattern observed in AD. The pattern of glucose metabolic changes in aMCI-old subjects was different, predominantly involving the frontal lobes and the left parietal lobe. Gray matter atrophy in aMCI-old subjects was less pronounced than that in the aMCI-young subjects, involving the hippocampus and the basal forebrain in both hemispheres CONCLUSIONS: Pathologic heterogeneity may be underlying the absence of AD-like glucose metabolic changes in older compared with younger patients with aMCI. This may be an important consideration for the clinical use of temporoparietal hypometabolism on FDG-PET as a marker for early diagnosis of AD in aMCI.
BACKGROUND AND PURPOSE:Decreased glucose metabolism in the temporal and parietal lobes on FDG-PET is recognized as an early imaging marker for the AD pathology. Our objective was to investigate the effects of age on FDG-PET findings in aMCI. MATERIALS AND METHODS: Twenty-five patients with aMCI at 55-86 years of age (median = 73 years) and 25 age- and sex-matched CN subjects underwent FDG-PET. SPM5 was used to compare the FDG uptake in patients in aMCI-old (>73 years) and aMCI-young (<or=73 years) groups with CN subjects. The findings in the aMCI-old patients were independently validated in a separate cohort of 10 aMCI and 13 CN subjects older than 73 years of age. RESULTS: The pattern of decreased glucose metabolism and gray matter atrophy in the medial temporal, posterior cingulate, precuneus, lateral parietal, and temporal lobes in aMCI-young subjects was consistent with the typical pattern observed in AD. The pattern of glucose metabolic changes in aMCI-old subjects was different, predominantly involving the frontal lobes and the left parietal lobe. Gray matter atrophy in aMCI-old subjects was less pronounced than that in the aMCI-young subjects, involving the hippocampus and the basal forebrain in both hemispheres CONCLUSIONS: Pathologic heterogeneity may be underlying the absence of AD-like glucose metabolic changes in older compared with younger patients with aMCI. This may be an important consideration for the clinical use of temporoparietal hypometabolism on FDG-PET as a marker for early diagnosis of AD in aMCI.
Authors: Felice T Sun; Roberta A Schriber; Joel M Greenia; Jiawei He; Amy Gitcho; William J Jagust Journal: Neuroimage Date: 2006-11-16 Impact factor: 6.556
Authors: Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers Journal: Alzheimer Dis Assoc Disord Date: 2006 Jan-Mar Impact factor: 2.703
Authors: Gregory A Jicha; Joseph E Parisi; Dennis W Dickson; Kris Johnson; Ruth Cha; Robert J Ivnik; Eric G Tangalos; Bradley F Boeve; David S Knopman; Heiko Braak; Ronald C Petersen Journal: Arch Neurol Date: 2006-05
Authors: Lisa Mosconi; Miroslaw Brys; Lidia Glodzik-Sobanska; Susan De Santi; Henry Rusinek; Mony J de Leon Journal: Exp Gerontol Date: 2006-07-12 Impact factor: 4.032
Authors: Prashanthi Vemuri; Jeffrey L Gunter; Matthew L Senjem; Jennifer L Whitwell; Kejal Kantarci; David S Knopman; Bradley F Boeve; Ronald C Petersen; Clifford R Jack Journal: Neuroimage Date: 2007-10-22 Impact factor: 6.556
Authors: Jerod M Rasmussen; Anita Lakatos; Theo G M van Erp; Frithjof Kruggel; David B Keator; James T Fallon; Fabio Macciardi; Steven G Potkin Journal: Biochim Biophys Acta Date: 2011-09-19
Authors: Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack Journal: Neurobiol Aging Date: 2011-10-21 Impact factor: 4.673
Authors: Zuzana Nedelska; Tanis J Ferman; Bradley F Boeve; Scott A Przybelski; Timothy G Lesnick; Melissa E Murray; Jeffrey L Gunter; Matthew L Senjem; Prashanti Vemuri; Glenn E Smith; Yonas E Geda; Jonathan Graff-Radford; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Clifford R Jack; Kejal Kantarci Journal: Neurobiol Aging Date: 2014-07-15 Impact factor: 4.673
Authors: Kejal Kantarci; Jeffrey L Gunter; Nirubol Tosakulwong; Stephen D Weigand; Matthew S Senjem; Ronald C Petersen; Paul S Aisen; William J Jagust; Michael W Weiner; Clifford R Jack Journal: Alzheimers Dement Date: 2013-01-30 Impact factor: 21.566
Authors: Bing Zhang; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Mandie Maroney-Smith; Anthony J Spychalla; David S Knopman; Clifford R Jack; Ronald C Petersen; Kejal Kantarci Journal: J Neuroimaging Date: 2014-07-15 Impact factor: 2.486